The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis
Open accessAbstract
Recurrence of hepatitis C virus (HCV) infection after liver transplantation (LT) is universal. However, the efficacy, tolerability and safety of combination interferon and ribavirin (IFN-RIB) or peginterferon and ribavirin (PEG-RIB) anti-viral therapies post-LT are uncertain. We performed a comprehensive search of major medical databases (1980-2005) and conference proceedings (1996-2005). The main outcome measure was sustained virological response (SVR, undetectable HCV RNA) at 6 months. Summary estimates were calculated using random-effects models. Twenty-seven IFN-RIB and 21 PEG-RIB studies were included. IFN-RIB was associated with a pooled SVR rate of 24% (95% CI, 20-27%), while PEG-RIB was associated with an SVR rate of 27% (23-31%). Pooled discontinuation rates were 24% (21-27%) with IFN-RIB and 26% (20-32%) with PEG-RIB. The pooled rate of acute graft rejection was 2% (1-3%) with IFN-RIB and 5% (3-7%) with PEG-RIB. IFN-RIB and PEG-RIB therapies in HCV infection post-LT were associated with similar but overall low SVR and were poorly tolerated. The rate of acute rejection was small. The therapeutic advantage of PEG-RIB therapy observed in non-transplant chronic HCV infection appears to be attenuated post-LT. Clinical trials are needed to evaluate reasons for this post-transplant therapeutic disadvantage and to find strategies to ameliorate them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., & Albrecht, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00097-0 · Cited by 749
Cited by
Berenguer, M., Palau, A., Aguilera, V., Rayón, J.-M., Juan, F. S., & Prieto, M. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02126.x · Cited by 283
Metadata
- Authors
- Wang, C. S., Ko, H. H., Yoshida, E. M., Marra, C. A., & Richardson, K.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 6
- Issue
- 7
- Pages
- 1586-1599
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1545862634
- Cited by
- 193
- References
- 1
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis. https://app.cochat.ai/papers/10.1111/j.1600-6143.2006.01362.x
- The paper
- Wang, C. S., Ko, H. H., Yoshida, E. M., Marra, C. A., & Richardson, K. (2006). Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2006.01362.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.